221 related articles for article (PubMed ID: 23360257)
1. Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase.
Batool S; Nawaz MS; Greig NH; Rehan M; Kamal MA
Antiinflamm Antiallergy Agents Med Chem; 2013; 12(2):129-35. PubMed ID: 23360257
[TBL] [Abstract][Full Text] [Related]
2. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.
Kamal MA; Qu X; Yu QS; Tweedie D; Holloway HW; Li Y; Tan Y; Greig NH
J Neural Transm (Vienna); 2008 Jun; 115(6):889-98. PubMed ID: 18235987
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
Kamal MA; Shakil S; Nawaz MS; Yu QS; Tweedie D; Tan Y; Qu X; Greig NH
CNS Neurol Disord Drug Targets; 2017; 16(7):820-827. PubMed ID: 28176640
[TBL] [Abstract][Full Text] [Related]
4. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Kamal MA; Al-Jafari AA; Yu QS; Greig NH
Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
[TBL] [Abstract][Full Text] [Related]
6. Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway.
Reale M; Di Nicola M; Velluto L; D'Angelo C; Costantini E; Lahiri DK; Kamal MA; Yu QS; Greig NH
Curr Alzheimer Res; 2014; 11(6):608-22. PubMed ID: 24359497
[TBL] [Abstract][Full Text] [Related]
7. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
Mazumder MK; Choudhury S
Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
[TBL] [Abstract][Full Text] [Related]
8. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
Ferrer I; Blanco R; Carmona M; Puig B
J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
Barai P; Raval N; Acharya S; Borisa A; Bhatt H; Acharya N
Behav Brain Res; 2019 Jan; 356():18-40. PubMed ID: 30118774
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
Kamal MA; Klein P; Yu QS; Tweedie D; Li Y; Holloway HW; Greig NH
J Alzheimers Dis; 2006 Sep; 10(1):43-51. PubMed ID: 16988481
[TBL] [Abstract][Full Text] [Related]
12. P38K and JNK pathways are induced by amyloid-β in astrocyte: Implication of MAPK pathways in astrogliosis in Alzheimer's disease.
Saha P; Guha S; Biswas SC
Mol Cell Neurosci; 2020 Oct; 108():103551. PubMed ID: 32896578
[TBL] [Abstract][Full Text] [Related]
13. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
14. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
15. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
16. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
[TBL] [Abstract][Full Text] [Related]
17. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
18. Novel compound VB-037 inhibits Aβ aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer's disease.
Chiu YJ; Hsieh YH; Lin TH; Lee GC; Hsieh-Li HM; Sun YC; Chen CM; Chang KH; Lee-Chen GJ
Neurochem Int; 2019 May; 125():175-186. PubMed ID: 30707915
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
[TBL] [Abstract][Full Text] [Related]
20. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]